<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00666549</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 07-0548-00106</org_study_id>
    <secondary_id>P01CA108671-01A2</secondary_id>
    <secondary_id>MPD-RC 106</secondary_id>
    <nct_id>NCT00666549</nct_id>
  </id_info>
  <brief_title>Research Tissue Bank</brief_title>
  <official_title>Research Tissue Bank</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Myeloproliferative Disorders-Research Consortium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study that will allow for the preservation and/or storage of a small portion one or more
      of the following tissues:

        -  Peripheral blood

        -  Bone marrow

        -  Bone marrow biopsy

        -  A phlebotomized unit of blood

        -  Spleen cells

        -  Toenail clippings

      This material will be used for the study of Myeloproliferative Disorders (MPD) by
      researchers. The goals of this research study are to understand the causes of MPDs, how to
      diagnose them more easily and how to treat them better. MPD is a disease affecting
      hematopoietic stem cells. Hematopoietic stem cells are cells that make blood cells. These
      stem cells grow in the center portion of the bones called bone marrow. Under some conditions,
      these cells are also found in blood. There are several diseases, which are classified as MPD.
      These include polycythemia vera (too many red blood cells), essential thrombocythemia (too
      many platelets), and idiopathic myelofibrosis (abnormal blood cells and fibers build up in
      the bone marrow). These syndromes carry a high risk of developing leukemia. It is important
      to continue to learn more about these blood cancers and to learn more about the effectiveness
      and potential side effects of various treatments.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To collect and store tissue specimens from patients with MPDs including PV, IM, ET. The samples will be used to conduct laboratory investigations to help define mechanisms involved in the pathophysiology and treatment of these disorders.</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Myelofibrosis</condition>
  <condition>Idiopathic Myelofibrosis</condition>
  <condition>Essential Thrombocythemia</condition>
  <condition>Polycythemia Vera</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood, bone marrow, bone marrow biopsy, toenail clippings, phlebotomized blood, spleen cells
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients diagnosed with Philadelphia chromosome negative myeloproliferative disorders (MPD)
        polycythemia vera (PV), idiopathic myelofibrosis (IM), and essential thrombocythemia (ET)
        are eligible and not currently participating in any MPD-RC treatment studies.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients diagnosed with Philadelphia chromosome negative myeloproliferative disorders
             (MPD) polycythemia vera (PV), idiopathic myelofibrosis (IM), and essential
             thrombocythemia (ET) are eligible.

          -  Newly diagnose MPD patients as well as previously treated for a MPD are eligible.

          -  Signed informed consent is required from each patient at the time of enrollment.

        Exclusion Criteria:

          -  Patients currently participating in experimental treatment arms of MPD-RC protocols,
             or other experimental treatment protocols are not eligible during the period they are
             on study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rona S Weinberg, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Myeloproliferative Disorders-Research Consortium</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lewis Silverman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rona S Weinberg, PhD</last_name>
    <phone>(212) 570-3412</phone>
    <email>rweinberg@nybloodcenter.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Palo Alto Medical Foundation Research Institute</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94301</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>David Leibowitz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weill Cornell University</name>
      <address>
        <city>Washington, D.C.</city>
        <state>District of Columbia</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Tsiporah Shore, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Georgetown</name>
      <address>
        <city>Washington, D.C.</city>
        <state>District of Columbia</state>
        <zip>20057</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Craig Kessler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Illinois at Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Damiano Rondelli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jerry Spivak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Roswell Park</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Minocher Battiwalla, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Lewis Silverman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Elizabeth Hexner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Josef Prachal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedali Riuniti di Bergamo</name>
      <address>
        <city>Bergamo</city>
        <state>IL</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Alessandro Rambaldi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Florence</name>
      <address>
        <city>Florence</city>
        <state>IL</state>
        <zip>60302</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Alessandro Vannucchi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Sweden</country>
  </removed_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 23, 2008</study_first_submitted>
  <study_first_submitted_qc>April 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2008</study_first_posted>
  <last_update_submitted>October 4, 2017</last_update_submitted>
  <last_update_submitted_qc>October 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myeloproliferative Disease</keyword>
  <keyword>Myelofibrosis</keyword>
  <keyword>Idiopathic Myelofibrosis</keyword>
  <keyword>Essential Thrombocythemia</keyword>
  <keyword>Polycythemia Vera</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Primary Myelofibrosis</mesh_term>
    <mesh_term>Polycythemia</mesh_term>
    <mesh_term>Polycythemia Vera</mesh_term>
    <mesh_term>Thrombocytosis</mesh_term>
    <mesh_term>Thrombocythemia, Essential</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

